FindTrial
Sign In

Xanomeline and Trospium Chloride Capsules

DRUG9 trials

Sponsors

Karuna Therapeutics, Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Conditions

SchizophreniaSchizophrenia; Psychosis

Phase 2

A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia
CompletedNCT03697252
Karuna TherapeuticsSchizophrenia
Start: 2018-09-18End: 2019-09-04Updated: 2020-10-26

Phase 3

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)
CompletedNCT04659174
Karuna TherapeuticsSchizophrenia
Start: 2021-02-01End: 2023-10-03Updated: 2024-10-28
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)
CompletedNCT04659161
Karuna TherapeuticsSchizophrenia, Schizophrenia; Psychosis
Start: 2020-12-16End: 2022-05-24Updated: 2023-12-12
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)
CompletedNCT04738123
Karuna TherapeuticsSchizophrenia, Schizophrenia; Psychosis
Start: 2021-04-06End: 2022-12-07Updated: 2024-12-09
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
CompletedNCT04820309
Karuna TherapeuticsSchizophrenia
Start: 2021-06-02End: 2024-05-24Updated: 2025-09-17
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
CompletedNCT05145413
Karuna Therapeutics, Inc., a Bristol Myers Squibb companySchizophrenia
Start: 2021-11-12End: 2025-03-19Updated: 2026-05-05
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
CompletedNCT05304767
Karuna Therapeutics, Inc., a Bristol Myers Squibb companySchizophrenia
Start: 2022-03-07End: 2026-03-25Updated: 2026-07-31
An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
TerminatedNCT05643170
Karuna TherapeuticsSchizophrenia
Start: 2022-11-08End: 2023-03-08Updated: 2024-06-12
A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
CompletedNCT05919823
Karuna TherapeuticsSchizophrenia
Start: 2023-05-29End: 2024-12-09Updated: 2025-12-17

Related Papers

Long-term efficacy, safety, and tolerability of xanomeline and trospium chloride in schizophrenia: A 52-week, open-label trial (EMERGENT-5).
2026-01-07
Xanomeline and Trospium Chloride Versus Placebo for the Treatment of Schizophrenia: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed
Neuropsychiatric Disease and Treatment2025-04-014 citations
Xanomeline and Trospium Chloride for the Treatment of Agitation Associated With Schizophrenia
The Journal of Clinical Psychiatry2025-03-243 citations
Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia
The Journal of Clinical Psychiatry2025-02-256 citations
SAFETY AND EFFICACY OF KARXT IN PATIENTS WITH SCHIZOPHRENIA IN THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EMERGENT TRIALS
The International Journal of Neuropsychopharmacology2025-02-014 citations
EFFICACY OF KARXT ON NEGATIVE SYMPTOMS IN ACUTE SCHIZOPHRENIA: AN ANALYSIS OF POOLED DATA FROM 3 TRIALS
The International Journal of Neuropsychopharmacology2025-02-011 citations
Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials.
2024-11-0215 citations
Pooled Analysis of EPS-Like Symptoms in the EMERGENT Program of KarXT in Schizophrenia
CNS Spectrums2024-10-011 citations
Efficacy of KarXT (Xanomeline Trospium) in Schizophrenia: Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials
CNS Spectrums2024-10-011 citations
Safety and Tolerability of KarXT (Xanomeline Trospium): Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials
CNS Spectrums2024-10-011 citations
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia
JAMA Psychiatry2024-05-01129 citations
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
2023-12-14137 citations
Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia.
2022-12-0344 citations
Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study
Translational Psychiatry2022-11-2194 citations
Antipsychotic Efficacy of KarXT (Xanomeline−Trospium)
The Journal of Clinical Psychiatry2022-05-0954 citations
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
New England Journal of Medicine2021-02-24306 citations